title: High sensitivity detection of HIV-1 using two genomic targets compared with single target PCR.
abstract: The genetic diversity of Human Immunodeficiency Virus type-1(HIV-1) has been shown to affect the performance of Nucleic Acid Testing (NAT) of Human Immunodeficiency Virus type-1. Although, majority NAT assays were designed to detect the conserved regions of HIV-1 mutations at the primer or probe binding regions may lead to false negatives. In this study, we evaluated the feasibility of detecting two genomic targets for enhanced sensitivity. A total of 180 tests using HIV-1 VQA RNA quantitation standard, 240 tests using EQAPOL HIV-1 viral diversity subtype panel, and 30 clinical plasma samples from Cameroon were evaluated. The analysis was based on probit and hit rate. The genomic targets LOD estimated by PROBIT for the gag target was 118 cps/ml (95%CI 64 cps/ml lower bound), Pol or POL/LTR was at 40 cps/ml (95%CI 17, 16 cps/ml), LTR 45 cps/ml (95%CI 20 cps/ml lower bound), and Gag/LTR at 67.8 cps/ml (95%CI 32 cps/ml lower bound). For HIV-1 subtypes the overall reactivity was 55-100% when tested at 100 and 1000 cps/ml and combination of genomic targets detection increased the reactivity to 100%. The plasma samples evaluation showed LTR or pol/LTR combination yielded higher sensitivity for patients with lower viral load (<40 cps/ml). We conclude that detection of two HIV-1 genomic targets improved sensitivity for detection of genetically diverse HIV-1 strains.
authors.affiliation: LMV/DETTD/OBRR/CBER/FDA, Bethesda, Maryland.|Voluntary Intern, Northwest High School, Germantown, Maryland.
authors.forename: Krishna
authors.initials: K
authors.lastname: Shah
authors.affiliation: LMV/DETTD/OBRR/CBER/FDA, Bethesda, Maryland.
authors.forename: Viswanath
authors.initials: V
authors.lastname: Ragupathy
authors.affiliation: Summer Intern, Thomas Jefferson High School for Science and Technology, Alexandria, Virginia.
authors.forename: Anusha
authors.initials: A
authors.lastname: Saga
authors.affiliation: LMV/DETTD/OBRR/CBER/FDA, Bethesda, Maryland.
authors.forename: Indira
authors.initials: I
authors.lastname: Hewlett
mesh_terms: D000328:Adult; D002163:Cameroon / Q000453:epidemiology; D017931:DNA Primers; D005260:Female; D014644:Genetic Variation; D016679:Genome, Viral; D015658:HIV Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods*; D012367:RNA, Viral / Q000097:blood; D012680:Sensitivity and Specificity; D019562:Viral Load
chemical_list: D017931:DNA Primers; D012367:RNA, Viral
keywords: HIV NAT assay; dual target; false negative; primer probe mis match; sensitivity